Gierke Hannes, Schaefer Kerstin, Gerlich Lukas, Willmann Ann-Cathrin, Bialetzki Verena, Boeck Georg, Pfrommer Teresa, Nolte Thomas, Weitschies Werner
Department of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport, University of Greifswald, 17489 Greifswald, Germany.
Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach, Germany.
Pharmaceutics. 2022 Nov 26;14(12):2608. doi: 10.3390/pharmaceutics14122608.
The formation of pharmacobezoars from suspensions of spray-dried amorphous solid dispersions (SD-ASDs) of new chemical entities (NCEs) and hydroxypropyl methylcellulose acetate succinate (HPMC-AS) represents a non-compound related adverse effect in preclinical oral toxicity studies in rodents. Whereas the contribution of the insolubility of the carrier polymer to this process taking place in the acidic environment of the rodent stomach is conclusive, unawareness of the extent of in vivo pharmacobezoar formation is adverse. In order to evaluate the risk of pharmacobezoar formation before in vivo administration, we subsequently introduce an in vitro model to assess the agglomeration potential of solid dispersions. To verify that the pharmacobezoar formation potential can be assessed based on the observed agglomeration potential, we conducted a sequence of experiments with two HPMC-AS-based SD-ASD formulations. In vitro, we found their different in vivo pharmacobezoar formation potential reflected by a significantly increased agglomerated mass of formulation 1 per day compared to formulation 2. In order to find an approach to reduce the agglomeration potential of solid dispersion from suspensions, we further applied the model to investigate the impact of the viscosity of the vehicle used to prepare suspensions on agglomerate formation.
新化学实体(NCEs)与羟丙基甲基纤维素琥珀酸酯(HPMC-AS)的喷雾干燥无定形固体分散体(SD-ASDs)混悬液形成药物性胃石,这在啮齿动物临床前口服毒性研究中是一种与化合物无关的不良反应。虽然载体聚合物的不溶性对在啮齿动物胃的酸性环境中发生的这一过程的影响是确凿的,但对体内药物性胃石形成程度的不了解是不利的。为了在体内给药前评估药物性胃石形成的风险,我们随后引入了一种体外模型来评估固体分散体的聚集潜力。为了验证能否基于观察到的聚集潜力来评估药物性胃石形成潜力,我们用两种基于HPMC-AS的SD-ASD制剂进行了一系列实验。在体外,我们发现它们不同的体内药物性胃石形成潜力通过制剂1每天的聚集物质量相比制剂2显著增加而得以体现。为了找到一种降低混悬液中固体分散体聚集潜力的方法,我们进一步应用该模型来研究用于制备混悬液的载体粘度对聚集体形成的影响。